Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
Canada
/
Pharmaceuticals & Biotech
/
Canopy Growth
WEED
Canopy Growth
Poland Restrictions And Rising Costs Will Constrain Global Expansion
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
12 Aug 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
CA$0
n/a
intrinsic discount
16 Aug
CA$1.77
Loading
1Y
-78.9%
7D
-1.7%
Author's Valuation
CA$0
n/a
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
CA$0
n/a
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-3b
572m
2014
2017
2020
2023
2025
2026
2028
Revenue CA$274.9m
Earnings CA$3.7m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
6.82%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.97%
Calculation
CA$3.66m
Earnings '28
x
0.00x
PE Ratio '28
=
CA$0
Market Cap '28
CA$0
Market Cap '28
/
526.95m
No. shares '28
=
CA$0
Share Price '28
CA$0
Share Price '28
Discounted to 2025 @ 5.97% p.a.
=
CA$0
Fair Value '25
